Condition: Colorectal Cancer (CRC) · Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced colorectal cancer
This description comes directly from the study's public registry record.
Fei Wu · 8615801390058 · wufei@imunopharm.com
Lin Shen, PhD · 8610 88196561 · doctorshenlin@sina.cn
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06718738